Technical analysis of Nuvectis Pharma, Inc. (NVCT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
Price Performance
| 1 month | +4.59% |
| 3 months | +58.25% |
| Year-to-date | +189.67% |
| 1 year | +253.31% |
| 3 years | +50.83% |
52-Week Range
| 52-week High | $29.28 |
| 52-week Low | $5.55 |
| Avg Volume (90d) | 270K |
Technical Indicators
| SMA 50 | $21.16 |
| SMA 200 | $12.60 |
| Beta | -0.21 |
| 30-day Volatility (annualised) | 65.8% |
| Price vs SMA 50 | +3.4% |
| Price vs SMA 200 | +73.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.71 | |
| 2025-11 | $6.24 | -7.0% |
| 2025-12 | $7.55 | +21.0% |
| 2026-01 | $8.11 | +7.4% |
| 2026-02 | $8.86 | +9.2% |
| 2026-03 | $7.73 | -12.8% |
| 2026-04 | $8.56 | +10.7% |
| 2026-05 | $9.75 | +13.9% |
| 2026-06 | $18.39 | +88.6% |
| 2026-07 | $21.52 | +17.0% |
| 2026-08 | $22.73 | +5.6% |
| 2026-09 | $21.87 | -3.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $21.87 |
| Market Cap | $580M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 52.60 |
| EV / EBITDA | -19.35 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.68 |